Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U De Giorgi

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2005
Is high-dose chemotherapy based on carboplatin, a late dose-intensification of a cisplatin-based salvage chemotherapy in germ cell tumour patients?U De Giorgi
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2001
Hyperthermia and hypoxia: new developments in anticancer chemotherapyN Zaffaroni, G Fiorentini, U De Giorgi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2005
Follow-up strategy of germ cell tumour patientsU De Giorgi, S Tana, G Rosti
European Journal of Neurology|May 20, 2003
Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patientG Ciucci, U De Giorgi, M Leoni, et al.
Tumori|May 11, 1999
[Adjuvant concomitant chemotherapy in pancreatic cancer]D Turci, A Cariello, U De Giorgi, et al.
Bone Marrow Transplantation|January 20, 2004
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experienceU De Giorgi, G Rosti, G Papiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2023
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?U De Giorgi, E F Giunta, E Verzoni, et al.
Journal of Chemotherapy (Florence, Italy)|January 29, 2005
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapyM Conti, U De Giorgi, V Tazzari, et al.
Cancer Immunology, Immunotherapy : CII|October 27, 2021
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapyV Conteduca, M Medri, L Mazzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
FDG-PET in the management of germ cell tumorU De Giorgi, A Pupi, G Fiorentini, et al.
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2005
Is high-dose chemotherapy based on carboplatin, a late dose-intensification of a cisplatin-based salvage chemotherapy in germ cell tumour patients?U De Giorgi
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2001
Hyperthermia and hypoxia: new developments in anticancer chemotherapyN Zaffaroni, G Fiorentini, U De Giorgi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2005
Follow-up strategy of germ cell tumour patientsU De Giorgi, S Tana, G Rosti
European Journal of Neurology|May 20, 2003
Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patientG Ciucci, U De Giorgi, M Leoni, et al.
Tumori|May 11, 1999
[Adjuvant concomitant chemotherapy in pancreatic cancer]D Turci, A Cariello, U De Giorgi, et al.
Bone Marrow Transplantation|January 20, 2004
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experienceU De Giorgi, G Rosti, G Papiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2023
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?U De Giorgi, E F Giunta, E Verzoni, et al.
Journal of Chemotherapy (Florence, Italy)|January 29, 2005
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapyM Conti, U De Giorgi, V Tazzari, et al.
Cancer Immunology, Immunotherapy : CII|October 27, 2021
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapyV Conteduca, M Medri, L Mazzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
FDG-PET in the management of germ cell tumorU De Giorgi, A Pupi, G Fiorentini, et al.
Pageof 9